Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r = +0.509 (P <0.001), whether pressure was reduced by spironolactone alone or combined with either hydrochlorothiazide or low dietary sodium, or by rapid sodium depletion alone. With small doses of spironolactone, restricting or liberalizing dietary sodium was associated with decreases or increases, respectively, in arterial pressure and plasma volume.
SUMMARY
Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r = +0.509 (P <0.001), whether pressure was reduced by spironolactone alone or combined with either hydrochlorothiazide or low dietary sodium, or by rapid sodium depletion alone. With small doses of spironolactone, restricting or liberalizing dietary sodium was associated with decreases or increases, respectively, in arterial pressure and plasma volume.
These results suggest 1) that the antihypertensive action of spironolactone is nonspecific and largely dependent on salt and water balance and 2) that maintenance of reduced plasma volume or extracellular fluid volume ( suggested as a practical test for the diagnosis of primary aldosteronism (1°A).' Hypertension caused by excessive production of electrolyte-active steroids responds dramatically to this treatment. However, a substantial proportion of patients with essential hypertension also respond well to spironolactone.2 Therefore, basic to the proposition that spironolactone allows recognition of hypertension associated with obvious or subtle steroid abnormalities3 is the question of whether the arterial pressure From the Research Division, The Cleveland Clinic Foundation and The Cleveland Clinic Educational Foundation, Cleveland, Ohio. Supported in part by grants HL 6835 from the National Heart and Lung Institute, National Institutes of Health, and 70-960 from the American Heart Association and 8557 from the Heart Association of Northeastern Ohio (American Heart Association). The study was presented in part at the annual meeting of the American Heart Association, Dallas, 1972. response represents some "specific effect" or is only a reflection of its natriuretic properties.
This study of 14 patients with proven 1°A was undertaken to determine whether arterial pressure response to spironolactone is a "specific effect" or simply a "nonspecific" response to salt and water depletion. The results suggest 1) that the action of spironolactone is nonspecific and largely dependent on salt and water balance in the body and 2) that some function of extracellular fluid volume (ECFV) mediates the associated hypertension of I°A.
Materials and Methods
Patients. Fourteen patients with 1°A (seven men, seven women) were the subjects of this study (table  1) . The clinical diagnosis was based on 1) hypokalemia, whether unprovoked or provoked by sodiumloading, 2) nonsuppressible aldosterone excretion rates (AER), and 3) low or normal plasma renin activity (PRA) which was not increased by sodium deprivation. All 'I -. '4) .i.i :. Statistical analysis was performed by accepted methods for calculating correlation coefficients (r), regression analyses, and significance tests.9 In patients on a sodium-restricted diet, arterial pressure was reduced by dosages of spironolactone usually considered inadequate. This response occurred within a week, about two to three weeks earlier than has been reported previously with doses of 400-600 mg per day.' 2 In P.P. (fig. 6) Figure 6 Arterial pressure response to decreasing doses of spironolactone during restriction of dietary sodium in one patient (P.P.). Other explanations as in figure 5 . Because spironolactone has little or no effect on the arterial pressure of secondary aldosteronism, it has been widely held that its striking effectiveness in 1°A depends on a specffic mineralocorticoid blockade rather than a nonspecific diuretic effect.' Indeed, the differential response to the thiazide diuretics and spironolactone has been advocated as distinguishing patients with "normokalemic" 1A from those with essential hypertension. Gwinup and Steinburg19 reported that arterial pressure is reduced by either spironolactone or thiazide diuretics in essential hypertensives while patients with 1°A respond only to spironolactone.
This study provides conclusive evidence that the ability of spironolactone to reduce arterial pressure in I°A is largely dependent on salt and water balance and not to any specific antagonism of the effects of electrolyte-active steroids. First, when salt intake was restricted, very small amounts of spironolactone were needed to sustain normal arterial pressure (fig. 6) 6 ). In the second patient ( fig. 7) it could be clearly shown that his arterial pressure responses to spironolactone therapy were largely dependent on sodium intake.
Finally, we have confirmed work of others1' 2, 10 showing that spironolactone is effective therapy for patients with aldosteronism and is particularly useful as a potassium-sparing agent when a potent natriuretic agent is being used as part of a regimen for treatment of the associated hypertension. In addition, we have shown that small doses are just as effective when combined with either sodium restriction or with conventional doses of hydrochlorothiazide. In view of these observations it is no longer advisable to use large doses of spironolactone as the treatment of choice in 1A. The therapeutic regimen suggested here has proved far superior to existing modes of medical therapy: it is much less expensive, predictable, rapid, and has none of the side effects (i.e., painful gynecomastia and decreased libido in the male, and menstrual irregularities and nausea in the female) commonly encountered in patients taking large doses of spironolactone. The therapeutic approach outlined in these studies has been found to be particularly useful in the preoperative preparation of the patient for surgery, and in the long-term management of cases not suitable for surgery.
